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A B S T R A C T
Pulmonary inflammatory diseases are a major burden worldwide. They have in common an influx of neutrophils.
Neutrophils secrete unchecked proteases at inflammation sites consequently leading to a protease/inhibitor
imbalance. Among these proteases, neutrophil elastase is responsible for the degradation of the lung structure via
elastin fragmentation. Therefore, monitoring the protease/inhibitor status in lungs non-invasively would be an
important diagnostic tool.
Herein we present the synthesis of a MeO-Suc-(Ala)2-Pro-Val-nitroxide, a line-shifting elastase activity probe
suitable for Electron Paramagnetic Resonance spectroscopy (EPR) and Overhauser-enhanced Magnetic
Resonance Imaging (OMRI). It is a fast and sensitive neutrophil elastase substrate with Km =15 ± 2.9 μM, kcat/
Km =930,000 s−1 M−1 and Km =25 ± 5.4 μM, kcat/Km =640,000 s−1 M−1 for the R and S isomers, re-
spectively. These properties are suitable to detect accurately concentrations of neutrophil elastase as low as
1 nM. The substrate was assessed with broncho-alveolar lavages samples derived from a mouse model of
Pseudomonas pneumonia. Using EPR spectroscopy we observed a clear-cut difference between wild type animals
and animals deficient in neutrophil elastase or deprived of neutrophil Elastase, Cathepsin G and Proteinase 3 or
non-infected animals.
These results provide new preclinical ex vivo and in vivo diagnostic methods. They can lead to clinical methods
to promote in time lung protection.
1. Introduction
Pulmonary inflammatory diseases represent a major health concern
worldwide as well as an economic burden. They include asthma, cystic
fibrosis (CF), chronic obstructive pulmonary disorder (COPD) (e.g.,
emphysema), acute respiratory distress syndrome and alpha-1-anti-
trypsin deficiency. For instance, COPD alone concerns a population
estimated to 175 million people and accounts for 3.2 million deaths
ranking it to the fifth cause of mortality worldwide [1]. Among the
precipitating factors for disease development are tobacco smoking,
urban air pollution and wood fire smoke. A common denominator of
pulmonary inflammatory diseases is the high neutrophil influx as seen
in CF or during the exacerbation phase of COPD. At inflammation sites,
neutrophils discharge four serine proteases into the extracellular en-
vironment whose concentrations surpass that of their corresponding
physiologic inhibitors resulting in protease/anti-protease imbalance
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causing tissue damage, hence progressive loss of lung functions.
Neutrophil elastase (NE), a potent protease, was shown to be the
main tissue-destructive actor because of its large repertoire of substrate
including structural proteins particularly elastin [2,3], a major lung
structural protein, although the four neutrophil proteases can act sy-
nergistically [4].
Therapeutically, lungs protection needs an adapted treatment with
protease inhibitors. However, preclinical research to setup such proto-
cols is impaired by the absence of a reliable imaging method to localize
deleterious enzyme activities in order to assess the actual protease/
antiprotease balance status before and after treatment. Ultimately, an
elastase activity imaging method valid for humans would detect lung
inflammation long before any irreversible tissue damage could occur.
Thus a treatment with inhibitors [5] or a change in habits could be
proposed “in time” to save the lungs.
Molecular imaging of the proteolytic activity is most easily done
using internally quenched fluorescent substrates. These substrates have
good enzymatic constants because they can encompass both the P and
P′ regions in the Schechter and Berger nomenclature [6]. There are
however several drawbacks of this method: substrate fluorescence
quenching is not complete thus causing long waiting times to eliminate
nonspecific “blinding” light, light tissue penetration is limited and
prevents imaging of deeply seated tissues or skull and three-dimen-
sional images are obtained by reconstruction.
Magnetic Resonance Imaging (MRI) methods have a superior true
3D space encoding and use wavelengths that only weakly interfere with
tissues. Electronic Paramagnetic Resonance (EPR) is a sensitive free
radical detection method suitable in visible light-opaque media. Stable
free radicals such as nitroxides or trityls can be detected or imaged in
vitro and in vivo. Since unpaired electrons are particularly sensitive to
the electronic environment some have been designed to display re-
sonance line broadening or shifting to detect various parameters. Hence
free radicals have been used for oximetry [7,8], redox status imaging
[9,10], pH measurement [11–14], water content measurement [15] or
to report on enzymatic activity [16–18]. EPR imaging (EPRI) can be
used with these free radicals. Unfortunately, due to the very fast re-
laxation of free electrons EPRI still remains slow and insufficiently re-
solved. Magnetic Resonance Imaging (MRI) is the method of choice to
deliver exquisite anatomical details but its low sensitivity so far pre-
vented molecular imaging such as enzyme activity imaging. Interest-
ingly, a line shifting substrate can also be monitored by Overhauser-
enhanced Magnetic Resonance Imaging (OMRI). OMRI is an emerging
imaging method designed to enhance NMR sensitivity. It is a double
resonance experiment transferring a part of the higher spin polarization
of an unpaired electron to the environing water protons (through the
electron-proton Overhauser effect) which enhances the MRI signal that
appears brighter [19].
It has been shown recently that OMRI at 0.2 T was able to reveal
brain tumors in mice models of glioma through intravenous injection of
a nonspecific nitroxide with high contrast on three-dimensional images
[20]. Moreover, a nonspecific prototype of the line-shifting nitroxide
later described in this study was able to reveal stomach and intestinal
enzymatic activity [18] (see reaction in Scheme 1). Both studies showed
that high contrast and high resolution images are possible in mice with
short recording times.
In this paper the synthesis of MeO-Suc-(Ala)2-Pro-Val-nitroxide
(molecule 3• in Scheme 1), the first of a new family of dedicated pro-
tease substrates based on line-shifting nitroxides is reported. Its cata-
lytic properties with neutrophil elastase and various enzymes were
studied using EPR spectroscopy.
The substrate was probed in broncho-alveolar lavages from a mouse
model of Pseudomonas aeruginosa lung infection with wild type and
several mice knocked-out for neutrophil serine proteases.
It is also shown that this substrate is suitable for Overhauser-en-
hanced Magnetic Resonance Imaging.
2. Material and methods
2.1. Organic synthesis
2.1.1. General remarks
1H nuclear magnetic resonance (NMR) spectra were recorded using
an internal deuterium lock at ambient temperatures on the following
instruments: Bruker AC 400 (400MHz) and Bruker AC 300 (300MHz).
Data are presented as follows: chemical shift (in ppm), integration,
multiplicity (s=singlet, d = doublet, t= triplet, m = multiplet, br =
broad, dd = doublet of doublets), coupling constant (J in Hz) and in-
tegration. 31P NMR spectra were recorded on a Bruker AC 300
(122MHz) and on a Bruker AC 400 (162MHz) spectrometers with
complete proton decoupling. Chemical shifts (δ) were reported in ppm
using TMS as internal reference for 1H and 13C NMR spectra, and 85%
H3PO4 for 31P NMR spectra. High-resolution mass spectra (HRMS)
were performed on a SYNAPT G2 HDMS (Waters) spectrometer
equipped with atmospheric pressure ionization source (API) pneuma-
tically assisted. Samples were ionized by positive electrospray mode as
follows: electrospray tension (ISV): 2800 V; opening tension (OR): 20 V;
nebulization gas pressure (nitrogen): 800 L/h. Low resolution mass
spectra were recorded on ion trap AB SCIEX 3200 QTRAP equipped
with an electrospray source. The parent ion (M+, [M+H]+, [M+Na]+
or [M+NH4]+) is quoted. Analytical thin layer chromatographies
(TLC) were carried out on Merck Kieselgel 60 F254 plates. Flash column
chromatographies were carried out on Merck Kieselgel 60 (230–400
mesh). Solvent system: gradients of DCM/MeOH; EtOAc/EtOH. All
experiments were performed under anhydrous conditions and an inert
atmosphere of argon and, except where stated, using dried apparatus
and employing standard techniques for handling air-sensitive materials.
For EPR measurements, samples with 0.5 mM concentration of nitr-
oxide were prepared in non-degassed solvents. Experiments were per-
formed indifferently on Elexsys, EMX or ER 100D Bruker machines (a
difference smaller than 0.1 G was noticed). EPR spectra were recorded
with a gain of 2 105 (72 dB for Elexsys), a modulation amplitude of
1.0 G, a sweep width of 150 G, a sweep time of 21 s, and a power of
20mW.
2.1.2. (9H-fluoren-9-yl)methyl-(S)-2-(((S)-1-(benzyloxy)-3-methyl-1-
oxobutan-2-yl)carbamoyl) pyrrolidine-1-carboxylate (2)
DIPEA (2mL, 11.5mmol) was added dropwise to a stirred suspen-
sion of L-Val-OBn·HCl (2.8 g, 11.5mmol) in dichloromethane (30mL) at
room temperature under an atmosphere of nitrogen. On dissolution, the
solution was cooled to 0 °C and Fmoc-L-Pro (4.26 g, 12.6 mmol) and 1-
hydroxybenzotriazole (1.86 g, 13.8 mmol) were added successively,
each in one portion. The suspension was stirred at 0 °C for a further
15min, and then DCC (2.85 g, 13.8 mmol) was added in one portion.
The mixture was allowed to warm to room temperature over the course
Scheme 1. Enzymatic activity on enol acetate 2• releasing 1•. Elastase targeting
substrate 3•.
of 18 h and then filtered, and the filtrate was evaporated in vacuo. The
residue was taken up in ethyl acetate and filtered, and the filtrate was
then washed with 10% aqueous citric acid solution followed by satu-
rated aqueous sodium bicarbonate solution. The combined organic
layers were dried and evaporated in vacuo to afford the crude product
which was purified by chromatography on silica using 3:2 petroleum
ether–EtOAc as eluent to yield the protected dipeptide 2 (5.94 g,
11.28mmol) as a light yellow solid (98%). [α]D20 – 50 (c 1.0, CHCl3).
1H NMR (300MHz, CDCl3) δ 7.68 (d, J = 7.5 Hz, 2H), 7.48 (s, 2H),
7.33–7.17 (m, 9.7H), 6.43 (br s, 0.3H), 5.20–4.82 (br m, 2H), 4.48–4.16
(m, 5H), 3.48–3.38 (m, 2H), 2.27–1.86 (m, 5H), 0.80 (d, J = 6.8 Hz,
2H), 0.75 (d, J = 6.6 Hz, 1H). 13C NMR (75MHz, CDCl3) δ 172.2,
171.6, 156.1, 155.2, 143.8, 141.3, 135.5, 128.6, 128.4, 128.3, 127.8,
127.1, 125.1, 120.0, 67.8, 67.0, 61.2, 60.4, 57.3, 56.7, 53.5, 47.6, 47.2,
47.0, 33.9, 31.5, 31.2, 28.2, 24.7, 23.7, 19.1, 17.6. HRMS (ESI) calc for
C32H35N2O5+: 527.2540 [M+H]+; found: 527.2547.
2.1.3. (((9H-fluoren-9-yl)methoxy)carbonyl)-L-prolyl-L-valine (3)
To a solution of 2 (5.94 g, 11.28mmol) in MeOH (80mL) was added
10% Pd/C (600mg), and the mixture was stirred for 10 h in hydrogen
atmosphere (1 atm). The reaction mixture was filtered through Celite,
and MeOH removed in vacuo to afford the fmoc protected dipeptide 3
in quantitative yield (4.92 g, 11.27mmol). [α]D20 – 46.1 (c 1.0, CHCl3).
1H NMR (300MHz, CDCl3) δ 7.65–7.12 (m, 8.7H), 6.52 (br s, 0.3H),
4.15–4.38 (br m, 5H), 3.41 (br m, 2H), 2.20–1.83 (m, 5H), 0.84–0.78
(m, 6H). 13C NMR (75MHz, CDCl3) δ 174.7, 172.1156.1, 155.6, 149.0,
143.9, 143.7, 141.3, 140.5, 127.7, 127.1, 126.9, 125.1, 124.0, 120.0,
119.8, 68.2, 67.9, 61.0, 60.4, 57.2, 56.7, 53.5, 47.5, 47.1, 42.4, 31.2,
31.0, 28.5, 24.6, 23.5, 19.1, 17.5. HRMS (ESI) calc for C25H29N2O5+:
437.2071 [M+H]+; found: 437.2073.
2.1.4. (S)-2-((S)-1-(((9H-fluoren-9-yl)methoxy)carbonyl)pyrrolidine-2-
carboxamido)-3-methyl- butanoic pivalic anhydride (4)
To an ice cold solution of dipeptide 3 (1.23 g, 2.83mmol) in 3mL
dry dichloromethane, Pivaloyl chloride (0.7 mL, 5.7mmol) was added
followed by the dropwise addition of triethyl amine (0.6 mL, 4,3mmol).
The reaction mixture was then allowed to stir at 0 °C for 1 h (TLC shows
completion of reaction) after which excess dichloromethane was re-
moved and the residue was taken up in diethyl ether. The solution was
then filtered through a celite bed. Removal of diethyl ether in vacuo
yielded the targeted anhydride 4 as a white foamy solid in a quanti-
tative yield which was used in the next reaction without any further
purification.
2.1.5. Methyl (S)-4-((1-(benzyloxy)-1-oxopropan-2-yl)amino)-4-oxobutanoate
(6)
DIPEA (17mL, 17mmol) was added dropwise to a stirred suspen-
sion of L-Ala-OBn·HCl (6.02 g, 27.9 mmol) in dichloromethane (70mL)
at room temperature under an atmosphere of nitrogen. On dissolution,
the solution was cooled to 0 °C and succinic acid monomethyl ester
(4.05 g, 30.7 mmol) and 1-hydroxybenzotriazole (4.52 g, 33.48mmol)
were added successively, each in one portion. The suspension was
stirred at 0 °C for a further 15min, and then DCC (6.91 g, 33.48mmol)
was added in one portion. The mixture was warmed to room tem-
perature in 18 h and then filtered, and the filtrate was evaporated in
vacuo. The residue was taken up in ethyl acetate and filtered, and the
filtrate was then washed with 10% aqueous citric acid solution followed
by saturated aqueous sodium bicarbonate solution. The combined or-
ganic layers were dried and evaporated in vacuo to afford the crude
product which was purified by chromatography on silica using 3:2
petroleum ether–EtOAc as eluent to yield 6 (7.2 g, 24.55mmol, 88%) as
a white solid. [α]D20 – 4.3 (c 1.0, CHCl3). 1H NMR (300MHz, CDCl3) δ
7.30–7.20 (m, 5H), 6.36 (s, 1H), 5.08 (dd, J= 18, 12 Hz, 2H), 4.54 (p, J
= 7.2 Hz, 1H), 3.58 (s, 1H), 2.66–2.54 (m, 2H). 2.50–2.4 (m, 2H), 1.32
(d, J = 7.2 Hz, 1H). 13C NMR (75MHz, CDCl3) δ 173.3, 172.9, 171.0,
135.4, 128.6, 128.4, 128.1, 67.1, 51.8, 48.2, 30.8, 29.2, 18.3. HRMS
(ESI) calc for C15H20NO5+: 294.1336 [M+H]+; found: 294.1340.
2.1.6. Methyl 4-(((S)-1-(((S)-1-(benzyloxy)-1-oxopropan-2-yl)amino)-1-
oxopropan-2-yl)amino)-4-oxobutanoate (7)
To a solution of 6 (7 g, 23.86mmol) in MeOH (80mL) was added
10% Pd/C (700mg), and the mixture was stirred for 10 h in hydrogen
atmosphere (1 atm). The reaction mixture was filtered through Celite
followed by MeOH removal in vacuo to yield quantitatively the free
acid (4.85 g, 23.8 mmol).
DIPEA (14.9mL, 83.52mmol) was added dropwise to a stirred
suspension of L-Ala-OBn·HCl (6.16 g, 28.56mmol) in dichloromethane
(100mL) at room temperature under an atmosphere of nitrogen. On
dissolution, the solution was cooled to 0 °C and the acid obtained in the
previous step (4.85 g, 23.8mmol) and 1-hydroxybenzotriazole (3.86 g,
28.56mmol) were added successively, each in one portion. The sus-
pension was stirred at 0 °C for a further 15min, and then DCC (5.89 g,
28.56mmol) was added in one portion. The mixture was warmed to
room temperature in 18 h and then filtered, and the filtrate was eva-
porated in vacuo. The residue was taken up in ethyl acetate and filtered,
and the filtrate was then washed with 10% aqueous citric acid solution
followed by saturated aqueous sodium bicarbonate solution. The com-
bined organic layers were dried and evaporated in vacuo to leave the
crude product which was purified by chromatography on silica using
3:2 petroleum ether–EtOAc as eluent to afford 7 (7.5 g, 20.71mmol) as
a white solid in 87% yield. [α]D20 – 44 (c 1.0, CHCl3). 1H NMR
(300MHz, CDCl3) δ 7.25 (s, 5H), 7.10 (s, 1H), 6.69 (s, 1H), 5.07 (dd, J
= 18, 12 Hz, 2H), 4.58–4.42 (m, 2H), 3.55 (s, 3H), 2.57 (dd, J = 10.0,
4.0 Hz, 2H), 2.41 (dd, J = 10.4, 4.5 Hz, 2H), 1.32 (d, J = 7.2 Hz, 3H),
1.27 (d, J = 7.0 Hz, 3H). 13C NMR (75MHz, CDCl3) δ 173.4, 172.4,
172.2, 171.3, 135.5, 128.6, 128.4, 128.1, 67.0, 51.8, 48.8, 48.2, 30.8,
29.2, 18.4, 17.8. HRMS (ESI) calc for C18H25N2O6+: 365.1707 [M
+H]+; found: 365.1696.
2.1.7. Methyl-4-(((S)-1-(((S)-1-((2,5-dioxopyrrolidin-1-yl)oxy)-1-
oxopropan-2-yl)amino)-1-oxo-propan-2-yl)amino)-4-oxobutanoate (8)
To a solution of 7 (7.5 g, 20.71mmol) in MeOH (80mL) was added
10% Pd/C (750mg), and the mixture was stirred for 10 h in hydrogen
atmosphere (1 atm). The reaction mixture was filtered through celite
followed by MeOH removal in vacuo to yield quantitatively the free
acid (5.68 g, 20.71mmol). [α]D20 + 8.7 (c 1.0, CHCl3). 1H NMR
(300MHz, MeOD) δ 4.39 (qd, J = 7.1, 3.1 Hz, 2H), 3.66 (s, 3H), 2.64
(dd, J = 10.1, 4.0 Hz, 2H), 2.52 (dd, J = 10.3, 4.0 Hz, 2H), 1.41 (d, J
= 7.3 Hz, 3H), 1.35 (d, J = 7.2 Hz, 3H). 13C NMR (75MHz, MeOD) δ
175.7, 174.9, 174.7, 174.0, 52.2, 50.1, 49.2, 31.2, 30.0, 18.0, 17.6.
HRMS (ESI) calc for C11H19N2O6+: 275.1238 [M+H]+; found:
275.1237.
To a solution of the free acid from above (484mg, 1.76mmol) and
N-Hydroxysuccinimide (203mg, 1.76mmol) in 7mL THF, DCC
(364mg, 1.76mmol) was added in one portion. The mixture was stirred
at room temperature for 18 h and then filtered, and the filtrate was
evaporated in vacuo to afford the NHS ester 8 as a white solid in
quantitative yield (650mg, 1.75mmol) which was used in the next
reaction without further purification. HRMS (ESI) calc for
C15H22N3O8+: 372.1401 [M+H]+; found: 372.1400.
2.1.8. Synthesis of R-4•
A solution of ketone R-1• (209mg, 0.71mmol) in dry THF (10mL)
was slowly added to solution of LiHMDS (1.0m solution in THF, 1.2mL,
1.21mmol, 1.70 equiv.) at 78 °C in dry THF (5mL). The mixture was
stirred for 3 h from− 78 °C to− 45 °C. Then, 4 (739mg, 1.42mmol, 2
equiv.) was slowly added as a cold (- 45 °C) solution in 10mL THF. The
mixture was stirred for 2.5 h, then it was poured quenched with satu-
rated aqueous NH4Cl solution and extracted with EtOAc. The combined
organic extracts were dried with MgSO4, filtered, and concentrated
under vacuo. Column chromatography of the residue gave starting
material R-1• (92mg, 0.31mmol) and the targeted product R-4•
(175mg, 0.25mmol, 65% based on recovered starting material) as a
red foamy solid. HRMS (ESI) calc for C36H42N2O8PNa+: 728.3545 [M
+Na]+; found: 728.3553, [α]D20 – 58.3 (c 1.0, CHCl3). EPR (CH2Cl2):
aN 14.9 G, aP 39.0 G.
2.1.9. Synthesis of S-4•
S-4• was prepared following the same procedure as that for R-4•.
Yield 229mg, 0.32mmol, 91% based on recovered starting material as
a red foamy solid from S-1• (208mg, 0.71mmol), recovered starting
material S-1• 105mg, 0.36mmol. HRMS (ESI) calc for
C36H42N2O8PNa+: 728.3545 [M+Na]+; found: 728.3553, [α]D 20 –
21.3 (c 1.0, CHCl3). EPR (CH2Cl2): aN 15.2 G, aP 39.10 G.
2.1.10. Synthesis of R-5•
To a solution of R-4• (275mg, 0.39mmol) in 20mL DCM at 0 °C,
DBU (69 μL, 0.46mmol) was added. The reaction mixture was stirred at
0 °C for 3 h (TLC showed completion of reaction) followed by column
purification to yield the deprotected R-4• in 74% yield (143mg,
0.29mmol).
Deprotected R-4• (143mg, 0.29mmol) and 8 (120mg, 0.32mmol)
was dissolved in 5mL anhydrous DMF and the mixture was allowed to
stir for 18 h at room temperature. Removal of DMF in vacuo followed by
column chromatography yielded R-5• in 34% overall yield (105mg,
0.14mmol). HRMS (ESI) calc for C33H56N5O12P+: 745.3658 [M+H]+;
found: 745.3662. EPR (CH2Cl2): aN 15.0 G, aP 38.9 G.
2.1.11. Synthesis of S-5•
Similar procedure as that of above was used for the synthesis of R-
5•, from S-4• (186mg, 0.26mmol) yielded the final product S-2• in 50%
overall yield (52mg, 0.07mmol). HRMS (ESI) calc for C33H56N5O12P+:
745.3658 [M+H]+; found: 745.3659. EPR (CH2Cl2): aN 15.0 G, aP
39.0 G.
2.2. Enzymes
Neutrophil Elastase, Porcine Pancreatic Elastase, Proteinase 3 and
Cathepsin G were purchased from Elastin Products Company (Missouri,
USA). Bovine chymotrypsin and trypsin-TPCK treated were from
Worthington (New Jersey, USA). Matrix Metallo Proteinases -2, -7 and
-9 were purchased from Calbiochem. Stock enzyme solutions were
prepared at about 10−5 M in buffer HEPES 50mM, 0.15M NaCl, pH 5,
stored at− 20 °C and later titrated as described under. All experiments
were done in HEPES buffer 50mMpH 7.4, 0.15M NaCl and IGEPAL
0.05%.
2.2.1. Enzymes titration
Enzyme's active sites in solution were quantified by spectro-
photometric titration using synthetic chromogenic reagents which
combined stoichiometrically with active sites (1:1). Chromogenic re-
agents: Succinyl-Ala-Ala-pro-phe-p-nitroanilide (Cathepsin G, chymo-
trypsin), MeO-succinyl-Ala-Ala-Pro-Val-p-nitroanilide (NE, Proteinase
3) (Elastin Products Company, USA), z-Phe-Arg-p-nitroanilide (trypsin-
TPCK) and Succinyl-Ala-Ala-Ala-p-nitroanilide (PPE) (BACHEM,
Switzerland) were prepared in dimethyl sulfoxide (DMSO). Trasylol
from bovine lung, trypsin inhibitor from soybean (SIGMA) and Eglin C
from leech (gift from Dr. H. P. Schnebli, Ciba-Geigy, Basel,
Switzerland), natural protease inhibitors, were dissolved in HEPES
buffer. Titrations of NE, PPE, proteinase 3 and cathepsin G were made
with Eglin C, titrations of chymotrypsin and trypsin-TPCK were made
with trasylol and trypsin inhibitor from soybean respectively. Activity
of inhibitors was assumed to be 100%. MMP-2,-7,-9 were all active on
the fluorescent substrate Dnp-Pro-Leu-Gly-Leu-Trp-Ala-D-Arg-NH2
(Bachem). Their concentration was inferred from the manufacturer
specifications.
2.3. EPR spectroscopy of peptide-nitroxide substrates
All samples were loaded in 75 μL (75mm) capillaries (BLAUBRAND
micropipettes,). Acquisitions were performed at 25 °C with a tempera-
ture controller (BIO-I, NOXYGEN, Germany) fitted to an EMXnano EPR
spectrometer (BRUKER, Germany), under the control of Xenon software
(BRUKER). Quantitation of substrate and product nitroxides at each
time of the kinetics was done by fitting with both reference spectra
using the Spinfit module of Xenon software. Substrate and product
concentrations were obtained using the included Spincount calibrated
module.
Enzymatic activity assays were carried out using the EPR spectro-
scopy to monitor the substrate hydrolysis.
2.3.1. Enzymatic specificity screening in vitro
A list of proteases, described in Enzymes section, with various
specificities and origins was tested in pursuit of an effective proteolytic
activity on the nitroxide. All experiments were done with 1 nM pro-
teases. Enzymatic reactions were initiated by adding a small volume of
substrate 25 μM. Kinetics was immediately recorded by EPR during 2 h.
EPR acquisition parameters were set as follows: Bo =3423 G, sweep
width = 120 G; sweep time =10 s, attenuation = 6 dB; delay between
scan =30 s; modulation amplitude = 1G; gain = 50 dB. Post proces-
sing was done with IGOR Pro (Wavemetrics, Lake-Oswego, OR, USA),
initial velocities from different enzymes were collected and compared
in a histogram.
2.3.2. Michaelis kinetics constants of NE with both peptide-nitroxide
isomers
Kinetic reactions were made with NE 1 nM by adding a range of 11
concentrations of substrate from 2.5 μM to 200 μM, prepared ex-
temporaneously to limit spontaneous hydrolysis. EPR acquisition
parameters were set as follows: Bo =3423 G, sweep width =120 G;
sweep time = 10 s, attenuation =6 dB; delay between scan =30 s;
modulation amplitude = 4G; gain =50 dB. Thus spectra were re-
corded at 10 s interval. Quantitation of substrate and product nitroxides
at each time of the kinetics was done by fitting with both reference
spectra using the Spinfit module of Xenon software. Substrate and
product concentrations were calculated using the included Spincount
calibrated module. Product concentrations were plotted as a function of
time. Initial velocities were extracted by linear regression on the linear
portion of the plot (less than 5% of substrate consumed) for each initial
substrate concentration. Initial velocities values were finally plotted
versus substrate concentration. Michaelis-Menten hyperbolic re-
presentation was built from the initial velocities and a nonlinear re-
gression analysis was performed using Michaelis-Menten equation:
=
× ×
+
V k E SS0
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0
. Enzymatic parameters, Km and kcat were determined
for both substrate isomers.
2.3.3. Neutrophil elastase activity in bronco alveolar lavage
Proteolysis was started by adding 1mM substrate in 30 μL of bronco
alveolar lavage (BAL) samples. Samples were then immediately loaded
in capillaries. EPR acquisition parameters were set as follows: Bo
=3423 G, sweep width = 120 G; sweep time = 10 s, attenuation
=25 dB; delay between scan = 30 s; modulation amplitude = 1G; gain
=40 dB. Kinetic reactions were followed for 8 h at 25 °C. All experi-
ments were repeated on 4 or 5 different mice. The resulting slope of
progress curves [Product] = f(time) were plotted against the various
genotypes in a histogram representation. Results were normalized with
the condition WT infected.
2.4. Mouse inflammation model
2.4.1. Generation of mice deficient in CG, NE, and PR3
Simultaneous deficiency of the Prtn3 and Ela2 gene cluster (129S6/
SvEv), deficiency in CG(129S6/SvEv-C57BL/6J), and deficiency in NE
(129S6/SvEv-C57BL/6J) were generated by targeted mutagenesis as
described elsewhere [21–23]. NE-PR3–deficient mice and CG-deficient
mice were crossbred to generate heterozygote-deficient progeny (F1).
The F1 progeny were intercrossbred to generate mice deficient in NE,
PR3, and CG, referred to as NSP-KO [3]. Mouse strains were subse-
quently backcrossed (eight generations) on a pure C57BL6/J back-
ground. Mice were housed in a pathogen-free facility with food and
water ad libitum and a 12-h light/dark cycle.
Animal handling and procedures were approved by the Animal
Studies Committee at our institution (Health and Animal Protection
Office, Châlons-en-Champagne, France, Authorisation number: 51–31)
in accordance with the guidelines of the Federation of European
Laboratory Animal Science Associations and following the European
Directive 2010/63/EU on the protection of animals used in scientific
procedures.
2.4.2. Bacteria and intranasal infection
P. aeruginosa H103 was kindly provided by Dr. Hancock
(Vancouver, BC, Canada) [24]. An overnight bacterial culture (1 mL)
was grown in Luria Bertani broth (10mL) at 37 °C to late exponential
phase (3 h). Bacteria were washed twice with PBS (pH 7.4) and the
optical density (OD) of the cultures was determined at 600 nm (1
OD600 nm ≈1× 109bacteria/mL).
Mice (n=5 mice/genotype) were challenged intranasally with
bacteria and sacrificed at fixed time points. Briefly, mice were an-
esthetized by intraperitoneal (intraperitoneal) injection of ketamine
hydrochloride (75mg/kg) and medetomidine hydrochloride (1mg/kg).
Next, mice were challenged intranasally with 50 μL of saline buffer
(PBS) containing a predetermined sublethal dose of bacteria (106 CFUs/
per mouse) [25]. Control mice (n=5 mice/genotype) were challenged
with 50 μL of sterile PBS alone. WT mice, NE-KO deficient mice and
NSP-KO mice were sacrificed at 24 h post-infection. At this time point,
mouse lungs were analyzed for inflammatory cell recruitment and de-
tection of free active NE. Of note, all types of mice displayed a morbid
state that was more marked in KO mice after 24 h.
2.4.3. BAL collection
Mice were sacrificed, and the lungs were gently perfused with saline
via the right ventricle. The trachea was exposed through a midline in-
cision and was cannulated using a sterile 22-gauge catheter (BD
Biosciences, Franklin Lakes, NJ). Lungs were lavaged in situ (BAL), with
1mL of PBS, pH 7.4, cycled in three times. Identical recoveries of BAL
(700 μL per mouse) were obtained for each mouse [26]. Total cell and
differential counts were immediately performed on aliquots of BAL
fluids. The remaining BALs were centrifuged, aliquoted, and stored in
− 80 °C until use.
2.5. OMRI
2.5.1. EPR cavity and MRI system
The OMRI system used in all experiments is an EPR cavity (Bruker,
Wissemburg, France) inserted at the center of Cirrus Open 0.2 T MRI
system (MRI Tech, Canada). This permanent magnet at 0.193 T is op-
erated at a proton frequency of 8.24MHz and maximal field gradient
strength was 20 mT/m in the three directions of space.
Electron spin saturation was carried out in the EPR cavity, which
has a cylindrical geometry (240mm diameter and 28mm width). An
opening (28mm diameter) in the middle of the cavity enabled sample
positioning. Its design and mode of operation, Transverse-Electric
TE011 mode, was the focus of the development in order to minimize the
impact of electromagnetic HF field [27] and to limit Eddy currents [17].
The HF amplification channel, including a synthesizer and two
specific amplifiers (RFPA, Artigues-pres-Bordeaux, France), generated
the HF wave. The EPR resonance frequency was around 5.4 GHz, ac-
cording to the central EPR frequency of the nitroxide of interest. The
resonant cavity was tuned and matched with the help of a network
analyzer (Agilent Technologies, Santa Clara, CA, USA) at this resonance
frequency.
2.5.2. Pulse sequences
2D magnetic resonance images were generated with a Gradient
Echo sequence. It was modified to include a continuous EPR saturation
during all the acquisition which started 300ms prior to the first NMR
RF pulse. All MR adjustments were done manually, using the same fixed
parameters: TE/TR=20/200ms, field of view 40 * 40mm2, Matrix size
64 * 64, flip angle 30°, receiver bandwidth 20 kHz, with and without HF
irradiation (SON and SOFF).
2.5.3. Overhauser enhancements and EPR frequency
The EPR irradiation frequency was adjusted on the 4th peak upfield
of the EPR spectrum of the nitroxide to have a specific excitation of the
nitroxide of interest. Frequency sweep experiments were carried out to
characterize OMRI response of substrate and product at 1mM each. The
Overhauser enhancement was calculated as the ratio of the absolute
value of the NMR signal-to-noise ratio (SNR) in the presence of electron
saturation divided by the SNR measured without electron saturation
(SOFF).
The DNP factor (DNPF) is defined as< Iz> /I0−1
where< Iz> stands for the expected value of proton magnetization in
the presence of EPR saturation and I0 is the equilibrium proton mag-
netization. Assuming a steady-state electron saturation,
= nDNPF (ρfs/ )γ /γ ,S I (1)
where γS and γI are the electron and proton gyromagnetic ratio,
respectively, ρ the electron-nucleus coupling factor, n the number of
EPR lines, s the saturation factor and f the leakage factor. The leakage
factor can be expressed as:
= +f r r. [c]/(R . [c]),1 1I0 1
where [c] is the nitroxide concentration, r1 its longitudinal relaxivity
and R1I0 is the proton longitudinal relaxation rate constant in the ab-
sence of nitroxide. Due to the negative sign of the electron gyromag-
netic ratio and the positive sign of the coupling factor (mostly dipolar in
liquids), the Overhauser effect induce an out-of-phase shift of the
proton magnetization and thus a negatively signed DNPF. The re-
lationship between the Overhauser enhancement and the DNPF is:
= −Overhauser enhancement |DNPF| 1
DNP factor vs nitroxide concentration were evaluated by curve fit-
ting to Eq. (1) with R1I0 = 0.4 s−1 and r1 (determined from inversion-
recovery experiments) as fixed parameters, and the product s.ρ as a
floating parameter.
Details on the theoretical background can be found in Overhauser
[28], Abragam et al. [29] and a summary is given in Mellet et al. [27].
Overhauser enhancements were finally plotted against EPR frequency
and specific irradiation frequency was selected for each nitroxide form
(Fig. 6). Lineshape were evaluated from curve fit to a lorentzian func-
tion. Nitroxide relaxivity was calculated from inversion-recovery ex-
periments [30]. Inversion times ranged from 10ms to 10 s. NMR signals
vs inversion delay were fitted to a single exponential recovery curve
and relaxation rate constants vs nitroxide concentration (0–2mM
range) were adjusted with a linear model.
2.5.4. Kinetic measurements in vitro
OMRI of proteolysis kinetics was performed both by looking at the
substrate consumption and by looking at the product formation in se-
parate experiments. Experiments were done in the presence of 40 nM
NE (product kinetic) and 20 nM NE (substrate kinetic). Kinetics of hy-
drolysis were started by adding 0.5mM substrate (product formation)
or 1mM (substrate consumption). Control experiments were carried out
without enzyme. For each nitroxide form, two sets of 2D images were
acquired at various time intervals with and without electron saturation
with the imaging parameters described above.
3. Results
3.1. Synthesis of the methoxy-succinyl-alanine-alanine-proline-valine-
nitroxide enol ester
As mentioned above, nitroxides 1•/2• exhibit high potential to in-
vestigate proteolysis both by EPR and OMRI. Recently, enantiomers of
1• were separated, identified and, then used for the preparation of the
peptide-nitroxide substrate (reported elsewhere [31]).
After applying a similar approach, (details of the synthesis mod-
ifications are published elsewhere [31]) peptide-nitroxides R-3• and S-
3• putatively specific of neutrophil elastase protease were prepared in
two steps (Scheme 2 and Material and Methods section), in the first
step, the condensation of the activated peptide 4 (Scheme 3A and see
Material and Methods section) with the enolate of R-1• to yield nitr-
oxide R-4•, and, in the second step, coupling of R-4• with the activated
peptide 8 (Scheme 3B) to afford R-3•. The same procedure was applied
to S-1• to yield S-3• (overall yield of 45%, see Material and Methods
section).
Activated peptides 4 and 8 were prepared according to conventional
procedures (Scheme 3A and B, respectively). That is, using the standard
DCC procedure Fmoc-protected L-proline 1 is coupled to benzyl-pro-
tected L-valine to afford dipeptide 2 in 98% yields. The latter is quan-
titatively debenzylated into dipeptide 3 which was transformed into
activated anhydride 4 using pivaloyl chloride (Scheme 2A) [32,33]. The
second fragment 8 was synthesized in 3 steps from Succinic acid
monomethyl ester 5 and used without further purification. Using DCC
coupling procedure, peptide 6 was prepared in 88% yield by coupling 5
with L-Ala-OBn.HCl. Debenzylation of 6 followed by coupling with L-
Ala-OBn.HCl provided the benzyl protected dipeptide 7 in 87% yields.
Dipeptide 7 was then deprotected and converted into its NHS ester 8
using N-hydroxy succinimide and DCC (Scheme 3B). [34] Crude 8 was
used in the preparation of R-3• and S-3• without further purification.
3.2. Enzyme kinetics of substrate to product hydrolysis by NE
3.2.1. Enzymatic hydrolysis of the substrate
Chemical structures of substrate and enzymatic reaction product are
illustrated in Scheme 4.
As a preliminary experiment, the kinetics of hydrolysis of the sub-
strate by neutrophil elastase was studied by EPR (Fig. 1).
The EPR parameters including nitrogen and phosphorus hyperfine
coupling constants (aN and aP respectively) as they appear before and
after hydrolysis of substrate in the presence of NE are reported in
Table 1.
Owing to the difference of 4.9 G in their aP values, substrate and
product spectra are sufficiently resolved to avoid peaks overlapping,
thus allowing individual quantification in a substrate/product mixture.
As described in Table 1, product's linewidth was 1.22 G while sub-
strate's linewidth was 1.84 G. Thus, for EPR spectroscopy measurements
the product will show a better sensitivity and for Overhauser-enhanced
MRI specific excitation of the product will provide a greater signal
enhancement compared to the substrate as outlined hereafter.
3.2.2. Determination of the Michaelis constants
Kinetics of consumption of substrate and formation of product were
monitored in the concentration range of 2.5–200 μM (Fig. 2).
Initial velocities were deduced from the slope of the linear part of
each progress curve displayed in Fig. 2. Finally, Michaelis-Menten plots
(Fig. 3) allowed us to determine Michaelis constants (Table 2).
Kinetic constants for R-3• derived from these measurements are Km
=15 μM and kcat = 14 s−1, indicating a catalytic efficiency, kcat/Km, of
940 000 s−1 M−1. Constants for S-3• are Km=25 μM and kcat= 16 s−1,
with kcat/Km, of 640 000 s−1 M−1. Both isomers thus display similar
kinetic constants, having a Km 4–7 fold lower than that of the reference
chromogenic substrate MeO-Suc-(Ala)2-Pro-Val-pNA and a catalytic
constant 6–9 fold higher [35]. These results suggest that better inter-
actions occur with the P′ part of the substrate, namely the nitroxide
group, than with the widely used paranitroanilide leaving group, as the
peptide that fills the P part was identical in the two substrates.
Scheme 2. Preparation of R-3•: (a) Reagents and conditions: a) LiHMDS, 4, THF,− 78 to− 45 °C, 65%; b) (1) DBU, DCM, 0 °C, 3 h; (2) 8, DMF, rt, 18 h, 34% for
both steps 1 and 2.
Scheme 3. Preparation of activated peptide 4 (A) and 8 (B). Reagents and conditions for (A): (a) L-Val-OBn, HOBT, DCC, DIPEA, DCM, 0 °C to rt, 18 h, 98%; (b)
Pd/C, H2, MeOH, 10 h, rt, quantitative; (c) t-BuCOCl, Et3N, 0 °C, 1 h; and for (B) (a) L-Ala-OBn.HCl, HOBT, DCC, DIPEA, DCM, 0 °C to rt, 18 h; (b) (1) Pd/C, H2, MeOH,
10 h, rt, (2) (a), 87% yield for both steps 1 and 2; (c) (1) Pd/C, H2, MeOH, 10 h, rt, (2) N-hydroxy succinimide, DCC, THF, rt, 18 h, quantitative yield for each step.
3.2.3. Specificity screening of the substrate
Enzyme specificity screening was carried out in vitro. Initial velo-
cities of product formation for various enzymes are shown in Fig. 4.
Of the proteases of different classes tested, only Neutrophil Elastase,
Proteinase 3 and Porcine pancreatic elastase were able to hydrolyze the
substrate into product at a significant rate. This narrow specificity is
similar to that observed for the paranitroanilide-based analogous sub-
strate. As NE and Proteinase 3 are two inflammation markers released
from neutrophils by various means including degranulation [36,37],
this substrate is very promising for the study of pulmonary in-
flammatory diseases. As expected for an elastase with similar substrate
preferences, Porcine Pancreatic Elastase (PPE) was also able to catalyze
substrate hydrolysis at a high rate of the same order of magnitude as
NE. Again, the selectivity of the peptide-linked nitroxide is similar to
the one of the paranitroanilide chromogenic substrate bearing the same
peptide. It is however irrelevant in the context of most inflammation
diseases since PPE is synthetized as an inactive pro-enzyme and acti-
vated only in the intestinal lumen. Thus, the simultaneous presence of
both enzymes is impossible except in pancreatitis where premature
activation of PPE coexists with a strong inflammation. These experi-
ments yielded similar results for isomers S and R.
3.2.4. Relevance to inflamed lung situations
To determine the relevance of this substrate for in vivo imaging of
inflammation, NE detection was carried out using bronchoalveolar la-
vages derived from a mouse model of Pseudomonas pneumonia char-
acterized by an acute pulmonary inflammation. Mice were intra nasally
challenged with sterile PBS or containing Pseudomonas aeruginosa [21].
To assess the accuracy and specificity of NE detection, mice deficient in
NE (NE-KO) or the three serine proteases namely NE, Proteinase 3 and
Cathepsin G (3KO) were employed along with their Wild Type litter-
mates (WT) [3]. Initial velocities were recorded by EPR after adding
1mM substrate directly in the BronchoAlveolar Lavages (BALs) (Fig. 5).
As expected, infected WT mice BALs contained the maximal enzy-
matic activity. Interestingly, the activity in infected NE-KO mice sam-
ples dropped by 50% compared to the infected WT samples.
Furthermore, 3KO lost 70% of the reference activity. Since Cathepsin G
is inactive and Proteinase 3 active on this substrate, this additional
activity decrease in 3KO can be confidently attributed to the absence of
Proteinase 3. All control mice displayed an activity in the range of that
corresponding to the control spontaneous dissociation. To further sup-
port our findings, prior addition of Batimastat, a broad spectrum matrix
metalloproteinase inhibitor to infected BALs had no effect on activity
measurements (data not shown). Thus, the detected activity stems ex-
clusively from the neutrophil proteases NE and to a lesser extent from
Proteinase 3. The apparent difference between the infected and unin-
fected 3KO samples is not statistically significant in this set of experi-
ments. The slightly higher values for the infected 3KO could never-
theless be easily explained by some minor enzyme activities brought by
the bacteria Pseudomonas. Pseudomonas elastase, however, cannot
contribute as seen in Fig. 4.
Clearly, enzymatic activities in the setting of tissue inflammation
can be detected by EPR in infected mouse BALs with this substrate.
Significantly, hydrolysis of this substrate is due to active neutrophil
proteases and hence represents a selective marker of inflammation.
3.3. Images of elastase activity using Overhauser-enhanced MRI
Recently, the discovery of nitroxide-based substrates undergoing
strong electronic resonance spectrum alteration upon enzyme action led
to the concept of “Overhauser switch” [17,18]. Overhauser-enhanced
imaging was proven possible in vitro and in vivo. Thus, the NE specific
substrate was probed as a potential polarizing agent through in vitro and
Scheme 4. Proteolysis reaction of MeO-Suc-(Ala)2-Pro-Val-(R)nitroxide enol ester into the ketone form of the nitroxide and a free peptide by neutrophil elastase
(NE). The reaction is the same with the isomer S.
Fig. 1. EPR spectroscopy of the line-shifting nitroxide: hydrolysis of 40 μM
substrate R-3• by 0.8 nM protease NE yielding the product R-1•. Five EPR
spectra are represented corresponding to five reaction steps: 6%, 25%, 50%,
75% and 100% of product formation. Only 6% of product was formed after the
first EPR acquisition. Spectrum without NE corresponds to substrate R-3• (0% of
product) whereas spectrum with NE at 100% illustrates the product R-1•.
Spectra (dark lines) are fitted by a linear combination of substrate and product
(blue lines). Hyperfine coupling of the unpaired electron with the phosphorus
atom 31P (spin ½) and with the nitrogen atom 14N (spin 1) provide 6 EPR lines.
Parameters aP and aN are phosphorus and nitrogen coupling constants deduced
from EPR product or substrate spectra. (For interpretation of the references to
color in this figure legend, the reader is referred to the web version of this
article.)
Table 1
EPR parameters of substrate and product. (a) Landé's factor (b) peak to peak
linewidth of the fourth line. Enzymatic reaction induces a change in the
phosphorus hyperfine coupling constant (aP) hence creating a shift of the EPR
lines. This shift can be used to measure an enzyme activity by EPR in vitro or to
create contrast in vivo by OMRI. The parameters were measured in HEPES
buffer 50mM at pH 7.4, 0.15M NaCl and Igepal 0.05%.
Nitroxides aN (G) aP (G) g(a) Linewidths (G) (b)
Substrate 15.5 38.4 2.0052 1.84
Product 14.9 43.3 2.0053 1.22
ex vivo OMRI experiments.
3.3.1. Properties of the substrate and the product as an OMRI contrast agent
The EPR irradiation frequency of the fourth line upfield was swept
by tuning the cavity of the OMRI setup and the resulting MRI signal was
plotted. The maximum signal enhancements were observed at distinct
electronic EPR frequencies: 5425.6MHz for the substrates R-3• or S-3•
and 5414.4MHz for the product 1• (Fig. 6) as predicted from the EPR
spectra.
As for the EPR spectrometry study (cf. Enzymatic hydrolysis of the
substrate), both lines are well separated and do not overlap. Linewidths
are narrow enough to easily observe high signal enhancement in OMRI
experiments. The full width at half maximum of the OMRI-derived EPR
spectra in Fig. 6 was 7.4MHz for the substrate R-3• and 4MHz for the
product R-1•. Thus, linewidths in OMRI data agree with the results
obtained by EPR spectrometry. Difference in linewidth values could be
explained by the difference in the molecular weight of each nitroxide
form (cleaved or uncleaved) as it acts on the tumbling rate and a
probable contribution of the conformational change that is expected to
modify the hyperfine coupling with the cycle and methyl protons.
Moreover, it can be noticed that the product EPR signal amplitude in-
creased about 1.5 times upon hydrolysis thus facilitating proteolysis
detection.
As the frequency domain of EPR irradiation in this OMRI experi-
ment is narrow compared to the linewidths, each nitroxide can thus be
A                  B
Fig. 2. Display of selected curves among those used for the calculation of the initial rate of product formation for a range of substrate concentration by 1 nM NE in
HEPES buffer pH7.4 at 25 °C. A: isomer R; B: isomer S.
Fig. 3. Michaelis-Menten plot: initial velocities observed at different substrate
concentrations (0–200 μM) in the presence of 1 nM NE. Both (R) and (S) sub-
strate isomers are represented (blue triangles: isomer S and green circles:
isomer R). Spontaneous dissociation for both isomers are also showed as dotted
lines (open circles: Isomer R; open triangles: Isomer S). Both plots are fitted
with the Michaelis-Menten equation (continuous lines). (For interpretation of
the references to color in this figure legend, the reader is referred to the web
version of this article.)
Table 2
Enzymatic Michaelis constants for the (R) and (S) substrate isomers.
R-3• S-3•
Km (μM) 15 (± 2.9) 25 (± 5.4)
kcat (s−1) 14 (± 0.9) 16 (± 1.1)
kcat/Km (s−1 M−1) 930,000 640,000
Fig. 4. EPR comparative kinetics of the nitroxide substrate isomer S hydrolysis
by 9 different proteases. Kinetics of hydrolysis of 1mM substrate was studied by
EPR at 25 °C with 1 nM of each enzyme: NE, Proteinase 3, Cathepsin G, Trypsin,
Chymotrypsin, PPE, MMP-2, MMP-7, MMP-9 and the metallo-elastase from
Pseudomonas Aeruginosa (P.A). Substrate spontaneous dissociation in HEPES
buffer is also represented as a control. Experiments were done in duplicate.
Error bars represent the two limit values.
observed selectively with specific irradiation. On one hand, irradiating
a sample with the product EPR frequency will give access to the en-
zymatic activity. On the other hand, irradiating at the EPR frequency of
the substrate will give access to its bio distribution.
The 1H longitudinal relaxivity r1 was measured through a classical
MRI experiment for the substrate 3• and the product 1• and were equal
to 0.40 s−1mM−1 and 0.42 s−1mM−1, respectively. Those results are
comparable to the relaxivity r1 of Oxo-TEMPO (0.5 s−1 mM−1) (un-
published results) which is characteristic of a water accessible electron.
The OMRI sensitivity at 0.2 T was investigated (Fig. 7). Maximum
DNP factors reached − 26 for the product at about 2mM, and − 6 for
the substrate at about 1.4 mM. It should be noted that enhancement is
higher for the product. This discrepancy might be the consequence of a
lower EPR saturation efficacy of the substrate EPR line, since the
electronic saturation is correlated to the nitroxide linewidth.
Interestingly, a DNP factor of − 3 corresponding to an Overhauser
enhancement of 2 (or to 200% contrast) remains for 0.09mM of pro-
duct (as inferred from Eq. (1) in the Material and methods section),
which is a concentration compatible with future in vivo experiments.
This result showed a very good sensitivity of the method as low sub-
strate and product concentrations can be detected with high contrast.
3.3.2. Enzyme kinetics by OMRI in vitro
Since the substrate and the product can be detected by OMRI en-
zyme activity imaging was probed. Hence, the substrate was reacted
with neutrophil elastase and the hydrolysis was monitored by OMRI.
Fig. 8 shows relevant images acquired with the EPR irradiation set at
the product or the substrate frequency as a function of time.
A maximum Overhauser enhancement of 5 for the substrate was
obtained at the beginning of the reaction whereas a maximum en-
hancement of 8 for the product was obtained at the end of the reaction.
The estimated catalytic constant by OMRI using the initial slope of the
time-resolved Michaelis kinetics (kcat = 6 s−1) revealed a similar value
than the one calculated by EPR (see Table 2). Thus this substrate is
suitable for the detection neutrophil elastase activity by Overhauser-
enhanced Magnetic Resonance Imaging. It is also an imaging method
suitable to visualize the bio distribution of the substrate.
4. Discussion
Molecular imaging of enzyme activity by MRI is a long-sought-after
tool. To achieve this, it was needed to produce a contrast and to trigger it
specifically via enzyme activity. Since enzyme concentrations are mostly
in the nanomolar range an amplification step was also necessary to
overcome the gap of sensitivity with MRI which essentially produces
images from the highly concentrated water protons. In this study high
contrast was given by Overhauser-enhanced MRI in the presence of a
nitroxide. The contrast was conditioned to enzyme catalysis by linking a
specific peptide to a line-shifting nitroxide. Thus by choosing the EPR
irradiating frequency of the “Overhauser switch” either the substrate or
the product (hence the enzyme activity) would produce contrast.
Furthermore, signal amplification naturally occurred from the enzyme
turn-over as long as fresh substrate was present. The first approach was
to target Neutrophil Elastase, a protease associated with numerous in-
flammatory diseases. After characterization, the substrate was success-
fully tested on samples from a Pseudomonas aeruginosa lungs infection.
Fig. 5. Rate of product formation in bronchoalveolar lavages from un-
challenged mice and mice infected by Pseudomonas aeruginosa (P.A.) for 24 h.
1 mM substrate was added extemporaneously. WT: wild type mice; NE-KO: mice
Knocked-out for NE; 3KO: mice knocked-out for three neutrophil proteases.
Control: spontaneous hydrolysis of the substrate. Significance bars are the result
of an ordinary one-way ANOVA Tukey's multiple comparisons test.
Fig. 6. Determination of the optimal excitation EPR frequencies for OMRI experiments: The EPR irradiation frequency of the fourth line upfield was swept and the
resulting MRI signal was plotted. Overhauser signal enhancement of the substrate R-3• (A) and product 1• (B) were fitted using a lorentzian model. The MRI B0 field
was 0.1936 T for the substrate and 0.1935 T for the product.
The difficult but successful grafting of a chosen peptide on the
shifting nitroxide core suggests that a new family of protease activity
probe can be designed. Furthermore, the acetate enol ester [18] and the
elastase-specific peptide enol ester have the same EPR spectrum and
yield the same product after hydrolysis. Thus, the same instruments and
the same settings will be valid regardless of the protease targeted. Ex-
panding the targeted proteases by varying the peptide would allow
exploring other pathologies like pancreatitis or tumors via their asso-
ciated specific protease activity.
4.1. The MeO-Suc-(Ala)2-Pro-Val-nitroxide is a specific and fast substrate
for elastase.
The specificity tests show that MeO-Suc-(Ala)2-Pro-Val-nitroxide is a
fast substrate for Neutrophil Elastase and in a lesser extent for
Proteinase 3. All other tested proteinases including serine proteinases
and matrix metallo proteinases are ineffective. Particularly, the metallo
elastase from Pseudomonas aeruginosa does not generate any product.
Thus, with the irrelevant exception of pancreatic elastase, this substrate
is a reliable marker of inflammation via neutrophil serine proteases. The
Fig. 7. DNP factor as a function of nitroxide concentration. A: Substrate 3• (Parameters: Saturation factor s= 0.25; coupling factor rho = 0.36; relaxivity r1 = 0.4 /s/
mM); B : Product 1• (Parameters : Saturation factor s= 1, coupling factor rho = 0.36; relaxivity r1 = 0.42/s/mM).
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Fig. 8. OMRI monitoring of substrate consumption and product formation from elastase proteolysis. A: 2D images selected from the corresponding time course
(highlighted points) of substrate consumption. The initial substrate concentration was 1mM and the proteolytic reaction was accelerated by adding 20 nM enzyme.
The EPR frequency was tuned at 5426MHz. B: 2D images selected from the corresponding time course (highlighted points) of product formation. The initial substrate
concentration was 0.5 mM and enzyme concentration was 40 nM. The EPR frequency was tuned at 5415MHz.
Michaelis constants for elastase reveal a better substrate than its opti-
cally active paranitroanilide analog. In mouse BALs from the present
acute inflammation model an activity from 1 nM of NE is detected. In
human, BALs are estimated to dilute the epithelial lining fluid of about
one hundred fold [38]. Thus, the concentration of NE in lungs of wild
type infected mice would be 100 nM in vivo. In this situation, using the
Michaelis constants, a concentration as low as 75 μM of substrate (5
times the Km) would generate 1.4 μM/s of product which would thus
reach 140 μM in 100 s. Such a product concentration generates an
OMRI contrast of 200% as deduced from the OMRI sensitivity plot. In
vivo imaging of acute inflammation should then be possible within a
short time provided that the substrate could be supplied quickly to the
lungs prior to OMRI. In the case of cystic fibrosis concentrations of
active elastase in the epithelial lining fluid are in the range of 2 μM even
for patients with mild lung disease [39]. This is 2000 fold the lower
limit of our method thus ensuring a fast and strong signal in a few
seconds.
4.2. Towards a new tool first for research then for diagnosis
The first expected impact of this study is to provide a useful and
very specific diagnostic tool for inflamed lungs. More specifically, the
goal is to perform molecular MRI of any protease/inhibitor imbalance
with a true 3D resolution firstly for Neutrophil Elastase but also
Cathepsin G, Proteinase 3, MMP-12 and marginally for NSP4. It would
then be possible to inventory the endangered areas in the lungs and
later verify that a protective treatment with protease inhibitors has
indeed inhibited the enzyme activity. This diagnosis at a molecular
scale could be done prior to any anatomical alteration. Abnormal pro-
teolysis would be visible thus at a much earlier stage of the disease
when lung can still be preserved. For instance, in the pseudomonas
aeruginosa infection model it was possible to monitor the inflammation
while the lungs were reversibly altered. Ultimately it could be used as a
monitoring tool for a personalized treatment until protease activity is
effectively inhibited. All images were performed using the same setup
as for in vivo imaging of mice published earlier. Thus, at shorter term,
the method could be used as a pre-clinical tool to develop protease
inhibition strategies for emphysema or cystic fibrosis using animal ex-
perimental models with a real-time monitoring of protease activity in-
hibition in vivo. To this end, studies are ongoing.
New diagnosis on human could be done using the presented nitr-
oxide substrate and EPR. For instance, since EPR is able to perform on
samples that are opaque to the visible light it could be used to detect
enzyme activity in tissue samples such as biopsies.
All OMRI experiments herein validated the use of the substrate
MeO-Suc-(Ala)2-Pro-Val-nitroxide as a specific proteolysis probe for
OMRI. Future in vivo experiments of proteolysis imaging will be done to
visualized pulmonary inflammation in situ. Application to human di-
agnosis with OMRI will require further development. This stems from
the EPR frequency that is about 650 times higher than NMR frequency.
Consequently, at 0.2 T the electron resonance frequency is in the mi-
crowave range around 5.4 GHz. While it is possible to make mouse
images this frequency is not suitable for larger animals because of low
penetration depth. Interestingly, MRI at very low field is a currently
active research area [40–44]. For instance at earth magnetic field the
EPR frequency of nitroxides is in the range of several dozens of MHz,
which allows convenient saturation of electron states and high pene-
tration depths suitable for humans.
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